Sage Therapeutics, Inc. (SAGE) Has Bearish Wedge Down Chart Pattern Trading At $166.34

April 17, 2018 - By Sheila Anderson

Sage Therapeutics, Inc. (NASDAQ:SAGE) Corporate Logo

Big Money Sentiment increased to 1.49 in Q4 2017. It has change of 0.28, from 2017Q3’s 1.21. The ratio is positive due to Sage Therapeutics, Inc. positioning: 27 sold and 56 reduced. 63 funds acquired holdings and 61 increased holdings. Investors holded 38.55 million in 2017Q3 but now own 41.45 million shares or 7.53% more.
Fred Alger Management Inc stated it has 6,500 shs or 0% of all its holdings. Balyasny Asset Limited Liability owns 261,200 shs. Millennium Management has 50,845 shs for 0.01% of their capital. First Republic Management Incorporated owns 2,942 shs. 34,776 were accumulated by Fiera Capital Corporation. The Maryland-based Price T Rowe Assoc Md has invested 0.17% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Great Point Prtnrs Ltd Liability Corp accumulated 200,000 shs. Weiss Asset Mngmt Limited Partnership holds 0.04% of its capital in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 2,620 shs. Los Angeles Capital Mngmt & Equity Rech holds 3,100 shs. Citadel Advisors Limited Liability Company holds 0% of its capital in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 36,951 shs. State Street holds 1.12M shs. Dubuque Bankshares has 0.05% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE). Loring Wolcott And Coolidge Fiduciary Advsr Limited Liability Partnership Ma reported 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). 5,754 were reported by Parallax Volatility Advisers Lp. Fincl Bank Of America De holds 0% or 67,090 shs in its capital.

Sage Therapeutics, Inc. registered $27.36 million net activity with 0 insider purchases and 3 insider sales since December 14, 2017. Kanes Stephen also sold $7.80M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) shs. On Tuesday, March 6 PAUL STEVEN M had sold 58,139 shs worth $10.00 million.

Sage Therapeutics, Inc. (SAGE)’s chart reviews a down wedge chart with $156.36 Target. That’s 6.00 % below today’s $166.34 share price. At our $156.36 Target, the company worth will be $456.90M less.

On during the last trading session the stock increased $3.39 or 2.08%, reaching $166.34.Currently Sage Therapeutics, Inc. is uptrending after 135.95% change in last April 17, 2017. SAGE has 64,278 shares volume. SAGE outperformed the S&P 500 by 124.40%.

Analysts await Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings on May, 8. They expect $-1.85 EPS, down 21.71 % or $0.33 from last year’s $-1.52 per share. After $-1.75 actual EPS reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 5.71 % negative EPS growth.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

In total 11 analysts cover SAGE Therapeutics (NASDAQ:SAGE). “Buy” rating has 11, “Sell” are 0, while 0 are “Hold”. 100% are bullish. With $277.0 highest and $80.0 lowest [Target] SAGE Therapeutics has $202.38 average [Target] or 21.67% above the current ($166.34) price. 23 are the (NASDAQ:SAGE)’s analyst reports since October 19, 2017 according to StockzIntelligence Inc. On Thursday, November 9 RBC Capital Markets maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) rating. RBC Capital Markets has “Buy” rating and $145.0 target. On Thursday, December 7 the stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given by Stifel Nicolaus. On Thursday, December 7 the firm has “Buy” rating given by BMO Capital Markets. On Wednesday, January 31 BMO Capital Markets maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) with “Buy” rating. On Tuesday, February 27 the stock has “Buy” rating by SunTrust. In Thursday, November 9 report BMO Capital Markets maintained the stock with “Buy” rating. On Thursday, December 7 the rating was upgraded by Chardan Capital Markets to “Buy”. The company rating was maintained by Canaccord Genuity on Monday, March 26. On Thursday, February 22 the rating was maintained by RBC Capital Markets with “Buy”. In Thursday, November 2 report RBC Capital Markets maintained it with “Buy” rating and $120.0 target.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.